Allarity Therapeutics (ALLR) Institutional Ownership $1.77 +0.11 (+6.63%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$1.76 -0.02 (-0.85%) As of 05/22/2026 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Allarity Therapeutics (NASDAQ:ALLR)CurrentInstitutional OwnershipPercentage11.53%Number ofInstitutional Buyers(last 12 months)8TotalInstitutional Inflows(last 12 months)$1.16MNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$21.29K Get ALLR Insider Trade Alerts Want to know when executives and insiders are buying or selling Allarity Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Chart & View Institutional Buying and Selling Data ALLR Institutional Buying and Selling by Quarter Allarity Therapeutics Major Shareholders & Ownership History ExportReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/14/2026 Renaissance Technologies LLC228,084$249K0.0%-7.9%1.475% 2/18/2026 XTX Topco Ltd33,644$36K0.0%N/A0.209% 2/12/2026 DRW Securities LLC122,741$133K0.0%N/A0.763% 2/12/2026 Renaissance Technologies LLC247,612$267K0.0%+274.1%1.540% 1/15/2026 Capital Advisors Inc. OK100,000$108K0.0%N/A0.633% 11/17/2025 Citadel Advisors LLC94,142$149K0.0%N/A0.648% 11/13/2025 Private Advisor Group LLC278,949$441K0.0%N/A1.921% 8/14/2025 Jane Street Group LLC26,365$27K0.0%N/A0.175% 8/12/2025 XTX Topco Ltd50,950$51K0.0%N/A0.338% 8/8/2025 Geode Capital Management LLC50,650$51K0.0%+49.3%0.336% 2/17/2025Stonepine Capital Management LLC67,289$79K0.1%N/A1.518% 11/15/2023Sabby Management LLC359,400$268K0.2%N/A13.165% 11/15/2023Armistice Capital LLC261,000$195K0.0%N/A9.560% ALLR Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of ALLR shares? During the previous two years, 9 institutional investors and hedge funds held shares of Allarity Therapeutics. The most heavily invested institutionals were Private Advisor Group LLC ($441K), Renaissance Technologies LLC ($249K), Citadel Advisors LLC ($149K), DRW Securities LLC ($133K), Capital Advisors Inc. OK ($108K), Stonepine Capital Management LLC ($79K), and Geode Capital Management LLC ($51K).Learn more on Allarity Therapeutics' institutional investors. What percentage of Allarity Therapeutics' stock is owned by institutional investors? 11.53% of Allarity Therapeutics' stock is owned by institutional investors. Learn more on ALLR's institutional investor holdings. Which institutional investors have been buying Allarity Therapeutics' stock? Of the 9 institutional investors that purchased Allarity Therapeutics' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Private Advisor Group LLC ($278.95K), Renaissance Technologies LLC ($181.43K), DRW Securities LLC ($122.74K), Capital Advisors Inc. OK ($100K), Citadel Advisors LLC ($94.14K), XTX Topco Ltd ($84.59K), and Stonepine Capital Management LLC ($67.29K). How much institutional buying is happening at Allarity Therapeutics? Institutional investors have bought a total of 904,946 shares in the last 24 months. This purchase volume represents approximately $1.16M in transactions. Which of Allarity Therapeutics' major shareholders have been selling company stock? The following institutional investors have sold Allarity Therapeutics stock in the last 24 months: Renaissance Technologies LLC ($19.53K). How much institutional selling is happening at Allarity Therapeutics? Institutional investors have sold a total of 19,528 shares in the last 24 months. This volume of shares sold represents approximately $21.29K in transactions. Related Companies Cue Biopharma Major Shareholders Anixa Biosciences Major Shareholders enGene Major Shareholders Upexi Major Shareholders Coya Therapeutics Major Shareholders Promis Neurosciences Major Shareholders NRx Pharmaceuticals Major Shareholders aTyr Pharma Major Shareholders FitLife Brands Major Shareholders Q32 Bio Major Shareholders This page (NASDAQ:ALLR) was last updated on 5/24/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredYour computer is about to become a museum pieceFor 67 years, chip-making meant slicing a single silicon wafer into hundreds of pieces. Three companies just a...Eagle Publishing | SponsoredGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...Behind the Markets | SponsoredThe worst mistake you can make with the SpaceX IPOThe $1.75 trillion SpaceX IPO is generating massive hype - but history shows retail investors who pile in on d...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allarity Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allarity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
